Finding the Right Addiction Treatment MD

What actually makes a physician the right fit for this

Looking for the right doctor while holding a career together is a lot to carry at once. You already know how healthcare works. What you need is a way to tell, quickly, whether the physician in front of you can actually treat a substance use disorder well—not just recognize one.

Fit comes down to four things. First, formal training in addiction care and comfort prescribing FDA-approved medications for opioid or alcohol use disorder, combined with counseling. SAMHSA is direct that medications paired with behavioral therapy work, and that the physicians who prescribe them should be trained in addiction medicine and coordinate with support services ¹. A physician who treats medication as "substituting one addiction for another" is not the right physician; that framing is a misconception the evidence refutes ¹.

Second, shared decision-making. The right MD asks about your work, your travel, your family, and your goals before writing anything. For alcohol use disorder, current evidence calls for offering pharmacologic treatment to people with moderate or severe AUD and choosing medication based on your circumstances, not a default ¹¹.

Third, a care model that fits your life—office-based visits, telehealth, or coordination with a program when clinically needed ². Fourth, humility about scope. A physician who knows when to co-manage with counseling or refer to a specialist is safer than one who claims to handle everything alone ⁸.

Those four together are what you're vetting for. The rest of this guide shows you how.

Credentials that separate an addiction-trained MD from a general prescriber

Any physician with a DEA registration can now prescribe buprenorphine. That's a good thing for access—and a hard thing for you, because it means the letters after a doctor's name matter more than ever when you're deciding who to trust with your treatment.

Here's what actually signals addiction-specific training:

• Board certification in addiction medicine (ABPM) or addiction psychiatry (ABPN). These are subspecialty certifications that require fellowship training or a documented practice pathway in addiction care. A physician who lists one of these has been formally evaluated on the exact clinical territory you're asking them to manage.
• Direct experience with the full MOUD toolkit—buprenorphine, naltrexone, and methadone. SAMHSA's TIP 63 is explicit that medications for opioid use disorder should be available to all patients with OUD, and that decisions about which medication and how long to stay on it should be individualized to the person, not set by an arbitrary cap ¹⁵. A physician who only offers one option, or who signals up front that they'll want you off medication within a fixed window, isn't practicing to the guideline.
• Routine use of the state prescription drug monitoring program (PDMP). CDC principles treat PDMP review as baseline practice for anyone prescribing or evaluating opioid therapy ⁹. Ask directly whether they'll pull your PDMP before the first prescription. The answer tells you how they think.
• Coordination with counseling and behavioral therapy. Medication plus counseling is the combination the evidence supports ¹. Your MD doesn't have to provide the therapy themselves, but they should have a working referral pathway and a plan for who communicates with whom.
• A clear position on scope. The CDC is direct that clinicians who can't provide OUD treatment themselves should arrange care with a specialist ⁸. A physician who names their limits—and has a warm handoff ready—is often safer than one who claims full comfort with every scenario.

Before you book, verify board certification through the ABMS or ABPN public directories, and ask the practice directly how many patients they currently treat for opioid or alcohol use disorder. "A few" is a fair answer for a primary care office with addiction training. "None right now" is your signal to keep looking.

Medications your MD should be comfortable prescribing

You don't need to become a pharmacologist to vet a physician. You do need to know what's on the shelf, so you can tell when someone is offering you the full toolkit and when they're quietly narrowing your options to what they're used to. SAMHSA is clear that medications combined with counseling are the standard of care for opioid and alcohol use disorders, and that the medication conversation should be individualized to you ^{1, 15}.

Here's what your MD should be able to walk through with you—by name, by mechanism in plain language, and by fit for your work, travel, and health history.

Where to start your search when specialists are scarce

Here's the piece most people don't realize until they start looking: fewer than 2,500 physicians in the entire U.S. hold a formal addiction medicine specialty ¹⁰. That figure covers specialists, not the much larger group of physicians who can prescribe MOUD—but it explains why calling a "top addiction doctor" and getting a two-week appointment isn't the norm. Your search strategy has to match that reality.

Work through the sourcing sequence in this order:

1. Start with your primary care physician. NIAAA is direct that a primary care visit is an important first step—these clinicians can prescribe medication themselves or refer you into a good pathway ². Federal policy changes removed the old buprenorphine waiver, so more primary care offices now prescribe MOUD directly ¹⁰. If yours has addiction training, you may not need to look further. If not, ask them for a specific referral, not a list.
2. Add a board-certified addiction medicine or addiction psychiatry specialist when your case is more complex—co-occurring depression or anxiety, prior treatment attempts, chronic pain on the chart, or a benzodiazepine question that a generalist shouldn't handle alone.
3. Use a telehealth MAT prescriber when in-person access is slow, geographically inconvenient, or a privacy risk. Buprenorphine can be initiated remotely under current DEA rules, with an in-person follow-up window defined by the regulation ⁴. This isn't a workaround; it's a covered, regulated care pathway ³.
4. Consider an OTP-affiliated MD when methadone is clinically indicated or when a more structured daily rhythm would help early on ¹².

One practical note: when specialist expertise isn't locally available, the 2024 OUD guideline update endorses mentoring and teleconsultation between your prescriber and a specialist ¹³. Ask about that arrangement. It's often the fastest way to get specialist-level care into a primary care relationship you already trust.

Comparing the four care models you'll actually choose between

Once you've decided a physician is worth vetting, the next call is which delivery model to put them inside. The same buprenorphine prescription looks very different when it runs through a primary care office, a specialist practice, a telehealth platform, or an opioid treatment program. Each model has a different rhythm, a different privacy profile, and a different medication scope. The table below lays out what actually varies between them—structural facts only, no invented numbers.

A few practical notes on reading that table. CMS pays office-based SUD treatment as a monthly bundle when the patient is prescribed buprenorphine or naltrexone, which is why that model runs on a monthly cadence rather than weekly visits ⁷. OTP payment, by contrast, is structured as a weekly bundle covering medication, counseling, and toxicology ⁶—a very different rhythm, and one that's harder to hide from a demanding calendar. Telehealth is not a workaround; DEA's 2025 rules explicitly allow remote buprenorphine initiation with a defined in-person follow-up, and Medicare's behavioral health telehealth coverage is permanent ^{3, 4}.

Most professionals end up in the first or third row—primary care with addiction training, or a telehealth prescriber—sometimes with a specialist consulting behind the scenes. The OTP model is powerful when it's the right clinical answer, but it's rarely the first stop for someone trying to hold a full work schedule together.

Privacy, telehealth, and continuity with your work

Discretion isn't a luxury when your name is on filings, patient charts, or a partnership agreement. It's part of the clinical plan. The good news is that the current regulatory picture actually favors you: telehealth for behavioral health and substance use disorders is permanently covered by Medicare when you're at home, and most commercial insurers have followed the same structure ³. That means an early-morning video visit from your kitchen, before the office day starts, is a real option—not a workaround.

Buprenorphine is the piece most professionals worry about, because it's a controlled substance. DEA's 2025 telemedicine rules keep remote buprenorphine initiation on the table for opioid use disorder, with a defined in-person follow-up window built into the regulation ⁴. You can start treatment through a video visit, get stabilized, and schedule the in-person step when your calendar allows. For alcohol use disorder medications, there's no controlled-substance layer at all—naltrexone, acamprosate, and disulfiram can be managed almost entirely through telehealth once your MD has a full picture of your health ¹¹.

A few practical moves protect continuity with your work:

• Ask how the practice handles records requests and release-of-information forms. Substance use disorder records have additional federal protections. Your MD should be able to explain, without hedging, what leaves their office and what doesn't.
• Use your home address and a personal email for intake, not your work information. Route pharmacy pickups through a location that isn't next door to your office if that matters to you.
• Confirm the telehealth platform your MD uses and whether visits can be scheduled in early-morning, evening, or cross-time-zone slots. A practice that only offers 10 a.m. Tuesday appointments isn't built for your life.
• Ask whether your primary care record and your addiction treatment record are kept separate or integrated. Neither answer is wrong—but you should know which one you're choosing.

Questions to ask on the first call

The first call—or the first ten minutes of a first video visit—tells you almost everything you need to know. You're not being difficult by asking real questions. You're doing the same due diligence you'd do on any decision this size. Write these down before you dial, and take notes on the answers.

• "Are you board-certified in addiction medicine or addiction psychiatry?" A direct yes or no. If no, ask what addiction-specific training they've completed and how many patients with opioid or alcohol use disorder they currently treat ¹⁵.
• "Which medications do you prescribe for opioid use disorder? For alcohol use disorder?" You want to hear buprenorphine, naltrexone, and a working knowledge of methadone referral for OUD; naltrexone, acamprosate, and disulfiram for AUD ^{1, 11}. A short list is a signal.
• "How do you decide which medication is right, and how long someone stays on it?" The answer should sound individualized, not formulaic. Arbitrary time caps aren't consistent with the guideline ¹⁵.
• "Can we do intake and follow-ups by telehealth, and how do you handle the in-person requirement for buprenorphine?" A prepared practice will describe the DEA follow-up window without hedging ⁴.
• "Who provides the counseling piece, and how do you communicate with them?" Medication plus counseling is the standard—your MD should have a real answer ¹.
• "How do you handle records, releases, and confidentiality for substance use treatment?" A confident, specific answer here matters more than a reassuring one.

If the person on the phone can't answer these, or gets defensive, that's information too. Keep looking.

When one MD isn't enough: building a small team

Very few professionals find one clinician who handles medication, therapy, logistics, and the small daily fires that come with holding a career together during treatment. That's not a failure of your search—it's how modern addiction care is actually structured. SAMHSA is direct that medication works best alongside counseling and behavioral therapies, which means at minimum you're looking at two people, not one ¹.

A workable team usually looks like this:

• A prescribing physician who owns the medication decisions, refills, and any medical coordination—your primary care MD with addiction training, an addiction medicine or addiction psychiatry specialist, or a telehealth MAT prescriber.
• A therapist or counselor for the behavioral work. Your MD should know who this person is by name and have a real communication pathway with them, not just a referral list ¹.
• A case manager or care coordinator to handle the connective work—records requests, pharmacy transfers when you travel, calendar logistics, communication between clinicians. This is the piece professionals underestimate and then quietly rely on most.
• A specialist consultant behind the scenes when your prescriber isn't a specialist themselves. The 2024 OUD guideline update endorses mentoring and teleconsultation between a treating clinician and a more experienced physician, which lets you keep the primary care relationship you trust while pulling in specialist judgment on the harder calls ¹³.

Ask your MD, on the first call, who else they expect to be involved and how those people talk to each other. If the answer is vague, you'll end up doing that coordination yourself—on top of everything else you're already carrying.

What structured, confidential care looks like at its best

There's a working model for high-accountability, discreet addiction care that's been quietly running for decades: physician health programs. When physicians themselves need treatment for a substance use disorder, they're often routed into PHPs—structured programs that combine medication, therapy, monitoring, and coordinated care under confidentiality protections. The outcomes are notable. Many PHPs report high five-year abstinence and return-to-work rates among participating physicians ¹⁶.

You're not enrolling in a PHP. But the design principles translate. What makes those programs work is the same thing that makes any professional's treatment work: a named prescribing physician, real behavioral therapy running alongside medication, someone coordinating the moving pieces, and a communication structure that protects your privacy while keeping the clinical team aligned ¹. Nothing improvised. Nothing left to you to project-manage between board meetings.

One caveat worth naming. The PHP literature also raises concerns about due process and coercion in some program structures ¹⁶. You're building something voluntary and yours. The lesson to borrow is the architecture—structured, confidential, coordinated—not the compulsion. Ask your MD, on that first call, what structure they can offer around your medication plan. If the answer sounds like a real system, you're in the right place.

Red flags and quiet dealbreakers

Some warning signs are obvious. A physician who dismisses medication, pushes detox-only treatment for opioid use disorder, or promises a fixed "you'll be off this in 90 days" timeline is not practicing to the evidence. CDC is direct that detox alone raises overdose risk ⁹, and TIP 63 is direct that duration should be individualized, not capped ¹⁵. If you hear either, keep looking.

The quieter dealbreakers matter just as much:

• No mention of counseling. Medication without a behavioral pathway isn't the standard of care ¹. If your MD doesn't ask who's providing therapy, that's a gap.
• Moralizing language. "Willpower," "trading one addiction for another," or any framing that sounds like judgment—SAMHSA explicitly refutes the substitution myth ¹. You want a clinician, not a critic.
• No plan for the in-person buprenorphine follow-up. A prepared practice describes the DEA window clearly ⁴. Vagueness here means logistics will fall on you.
• Refusal to coordinate with your other clinicians. Isolation isn't discretion. It's a red flag.

Trust what the first conversation tells you. It rarely gets better later.

References

1. Medications for Substance Use Disorders | SAMHSA. https://www.samhsa.gov/medications-substance-use-disorders
2. Treatment for Alcohol Problems: Finding and Getting Help. https://www.niaaa.nih.gov/publications/brochures-and-fact-sheets/treatment-alcohol-problems-finding-and-getting-help
3. MLN1986542 – Medicare & Mental Health Coverage. https://www.cms.gov/files/document/mln1986542-medicare-mental-health-coverage.pdf
4. DEA Announces Three New Telemedicine Rules that Continue to Support Patient Access to Care. https://www.dea.gov/press-releases/2025/01/16/dea-announces-three-new-telemedicine-rules-continue-open-access
5. Screening, Brief Intervention & Referral to Treatment (SBIRT) Services. https://www.cms.gov/outreach-and-education/medicare-learning-network-mln/mlnproducts/downloads/sbirt_factsheet_icn904084.pdf
6. OTP Payment Rates - CMS. https://www.cms.gov/medicare/payment/opioid-treatment-programs-otp/billing-payment/otp-payment-rates
7. 2024-03-07-MLNC - CMS. https://www.cms.gov/training-education/medicare-learning-network/newsletter/2024-03-07-mlnc
8. Opioid Use Disorder: Treating | Overdose Prevention - CDC. https://www.cdc.gov/overdose-prevention/hcp/clinical-care/opioid-use-disorder-treating.html
9. Guideline Recommendations and Guiding Principles - CDC. https://www.cdc.gov/overdose-prevention/hcp/clinical-guidance/recommendations-and-principles.html
10. Most Americans don't know that primary care physicians can prescribe addiction treatment. https://nida.nih.gov/news-events/news-releases/2024/06/most-americans-dont-know-that-primary-care-physicians-can-prescribe-addiction-treatment
11. Treatment of Alcohol Use Disorder - NCBI Bookshelf. https://www.ncbi.nlm.nih.gov/books/NBK561234/
12. Federal Guidelines for Opioid Treatment Programs. https://library.samhsa.gov/sites/default/files/federal-guidelines-opioid-treatment-pep24-02-011.pdf
13. Management of opioid use disorder: 2024 update to the national clinical practice guideline. https://pmc.ncbi.nlm.nih.gov/articles/PMC11573384/
14. “We need all hands on deck”: characterizing addiction medicine training program directors’ perspectives on workforce needs. https://pmc.ncbi.nlm.nih.gov/articles/PMC11837306/
15. TIP 63: Medications for Opioid Use Disorder. https://store.samhsa.gov/sites/default/files/SAMHSA_Digital_Download/pep21-02-01-002.pdf
16. Physician Health Programmes and Addiction Treatment. https://www.bmj.com/content/361/bmj.k2110